Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17243880 | 0.86 | CTSD (0.31) | CTSDCTSLCTSBCTSS | |
| SCHEMBL26926319 | 0.84 | CTSD (0.36) | CTSDCTSLCTSBCTSS | |
| SCHEMBL5834019 | 0.83 | CTSD (0.33) | CTSDCTSLCTSBCTSS | |
| SCHEMBL22733859 | 0.80 | CTSD (0.35) | CTSDCTSLCTSBCTSS | |
| SCHEMBL31048215 | 0.76 | CTSD (0.34) | CTSDCTSLCTSBCTSS | |
| SCHEMBL17969814 | 0.75 | NAMPT (0.31) | CTSDCTSLCTSBCTSS | |
| SCHEMBL18988730 | 0.75 | GAA (0.33) | — | |
| SCHEMBL4669068 | 0.73 | CTSD (0.35) | CTSDCTSLCTSBCTSS | |
| SCHEMBL2334851 | 0.72 | GAA (0.32) | — | |
| SCHEMBL24854873 | 0.72 | ADRB2 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309252-B2 | Pyrrolopyrimidine compounds as inhibitors of CDK4/6 | NOVARTIS AG (CH) | 2016-04-12 | — | — | US | disclosed |
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099737-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS INHIBITORS OF CDK4/6 | CDK4, CDK6, CCNT1 | CTSD 3791/4885CTSL 2739/4885CTSB 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.